Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02759120 · ClinicalTrials.gov registry record · Phase 3
CleanUP IPF for the Pulmonary Trials Cooperative
A Phase 3 study, sponsored by Weill Medical College of Cornell University.
- Terminated
- Registry status
- Phase 3
- Development phase
- 513
- Enrollment target
NCT02759120: Clinical Trial Phase 3 study, sponsored by Weill Medical College of Cornell University.
NCT02759120 is a Phase 3 study that was terminated before completion, run by Weill Medical College of Cornell University. The registered enrollment target is 513 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (34% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02759120, a Phase 3 study, was terminated before completion, sponsored by Weill Medical College of Cornell University.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 513 participants
- Enrollment target
Study Summary
The purpose of this study is to compare the effect of standard care, versus standard of care plus antimicrobial therapy (co-trimoxazole or doxycycline), on clinical outcomes in patients diagnosed with idiopathic pulmonary fibrosis (IPF).
Interventions
- DRUG Antimicrobial therapy: Co-trimoxazole or Doxycycline
- OTHER No Intervention: Standard of Care
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 513 participants |
| Start Date | 2017-03-22 |
| Est. Completion | 2020-03-16 |
| Phase | Phase 3 |
Why NCT02759120 stopped before completion
NCT02759120 is an interventional study that assigns participants to a tested intervention. The registered 513 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (34% lower).
The record links to 0 conditions, and to 2 interventions - of which Antimicrobial therapy: Co-trimoxazole or Doxycycline is the first listed.
NCT02759120 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02759120 about?
NCT02759120 is a clinical study titled "CleanUP IPF for the Pulmonary Trials Cooperative". The purpose of this study is to compare the effect of standard care, versus standard of care plus antimicrobial therapy (co-trimoxazole or doxycycline), on clinical outcomes in patients diagnosed with idiopathic pulmonary fibrosis (IPF).
What is the current status of trial NCT02759120?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 513 participants. The study started on 2017-03-22. Estimated completion is 2020-03-16.
What interventions are being tested in trial NCT02759120?
The interventions under investigation include: Antimicrobial therapy: Co-trimoxazole or Doxycycline (DRUG), No Intervention: Standard of Care (OTHER).
Who is sponsoring clinical trial NCT02759120?
This trial is sponsored by Weill Medical College of Cornell University, which has 701 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02759120's enrollment target sits among peer trials
513 727th of 2000 higher than 1,273 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05691244 · 514 participants · Phase 3
Assess the Safety and Efficacy of Sovateltide in Patients With Acute Cerebral Ischemic Stroke
- NCT06585488 · 514 participants · Phase 1
A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in Participants With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplification
- NCT06716606 · 514 participants · Phase 3
A Study to Investigate the Long-term Safety and Efficacy of Belimumab in Adults With Interstitial Lung Disease (ILD) Associated With Systemic Sclerosis (SSc) and Other Connective Tissue Diseases (CTD) (BLISSconneCTD-OLE)
- NCT05005403 · 512 participants · Phase 1
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC), Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors, Receiving Intravenous (IV) Infusion of Azirkitug (ABBV-514) Alone or in Combination With Budigalimab or Bevacizumab
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI